GlassScriptPhysician profile
Kin C Wong
NPI 1891808507
$1,433.22
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $197.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $361.44 | 2019 | |
| Genzyme Corporation | $238.97 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $208.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.73 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $125.17 | 2019 | |
| Genentech USA, INC. | $49.05 | 2019 | |
| Philips North America LLC | $41.64 | 2019 | |
| Pfizer INC. | $37.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.00 | 2019 | |
| Merck Sharp & Dohme LLC | $18.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kin Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.